VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on April 12, 2013. The report addresses a corporate event occurring on the same date regarding the assignment of a Securities Purchase Agreement and Voting Agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to a specific transaction:
- Transaction Value: $36.0 million
- Shares Involved: 72 million shares of Common Stock
Material Changes
The material change reported is the consent by the Company to the assignment of the Assigned Documents (Securities Purchase Agreement and Voting Agreement) originally entered into on April 8, 2013. The assignee is Bergamo Acquisition Corp PTE, LTD ("Bergamo"). Under this assignment, Bergamo assumed all obligations, including the commitment to purchase the 72 million shares for $36.0 million.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the specific transaction details. No unusual items were disclosed.
Key Facts for Investor Verification
- Verify the status of the $36.0 million capital raise from Bergamo Acquisition Corp PTE, LTD.
- Confirm the closing date and settlement of the 72 million share issuance.
- Review the original Securities Purchase Agreement and Voting Agreement filed as Exhibits 10.1 and 10.2 to the April 8, 2013 Form 8-K for specific terms and conditions.